Haematologica最新文献

Fit, unfit, or frail? Now easier to tell for Hodgkin lymphoma. 健康，不健康，还是虚弱？现在更容易分辨何杰金氏淋巴瘤了。

IF 10.1 1区医学

Haematologica Pub Date : 2025-07-17 DOI: 10.3324/haematol.2025.288033

Alison J Moskowitz

引用次数: 0

Leukemia stem cells in acute myeloid leukemia-mimicking "space and time continuum"? 急性髓系白血病干细胞模拟“时空连续体”？

IF 10.1 1区医学

Haematologica Pub Date : 2025-07-17 DOI: 10.3324/haematol.2025.288003

Adriana Plesa,Christophe Roumier

引用次数: 0

Long non-coding RNA LINC00926 is a biomarker for naïve B-cells with prognostic value in advanced stage classic Hodgkin Lymphoma. 长链非编码RNA LINC00926是naïve b细胞的生物标志物，在晚期经典霍奇金淋巴瘤中具有预后价值。

IF 10.1 1区医学

Haematologica Pub Date : 2025-07-17 DOI: 10.3324/haematol.2025.287524

Ingram Iaccarino,Thomas Beder,Sarah Reinke,Peter Borchmann,Bastian Von Tresckow,Michael Altenbuchinger,Wolfram Klapper

引用次数: 0

Comparative single-cell lineage bias in human and murine hematopoietic stem cells. 比较人类和小鼠造血干细胞的单细胞谱系偏见。

IF 8.2 1区医学

Haematologica Pub Date : 2025-07-17 DOI: 10.3324/haematol.2025.287897

Isaac Shamie, Meghan Bliss-Moreau, Jamie Casey Lee, Ronald Mathieu, Harold M Hoffman, Bob Geng, Nathan E Lewis, Yanfang Peipei Zhu, Ben A Croker

{"title":"Comparative single-cell lineage bias in human and murine hematopoietic stem cells.","authors":"Isaac Shamie, Meghan Bliss-Moreau, Jamie Casey Lee, Ronald Mathieu, Harold M Hoffman, Bob Geng, Nathan E Lewis, Yanfang Peipei Zhu, Ben A Croker","doi":"10.3324/haematol.2025.287897","DOIUrl":"https://doi.org/10.3324/haematol.2025.287897","url":null,"abstract":"<p><p>The commitment of hematopoietic stem cells (HSC) to myeloid, erythroid, and lymphoid lineages is influenced by microenvironmental cues, and governed by cell-intrinsic and epigenetic characteristics that are unique to the HSC population. To investigate the nature of lineage commitment bias in human HSC, mitochondrial single cell (sc) ATAC-Sequencing (mtscATAC-Seq) was used to identify somatic mutations in mitochondrial DNA to act as natural genetic barcodes for tracking the ex vivo differentiation potential of HSC to mature cells. Clonal lineages of human CD34+ cells and their mature progeny were normally distributed across the hematopoietic lineage tree without evidence of significant skewing. To investigate commitment bias in vivo, mice were transplanted with limited numbers of long-term HSC (LT-HSC). Variation in the ratio of myeloid and lymphoid cells between donors, although suggestive of a skewed output, was not altered by increasing numbers of LT-HSC. These data suggest that the variation in myeloid and lymphoid engraftment is a stochastic process dominated by the irradiated recipient niche with minor contributions from the cell-intrinsic lineage bias of LT-HSC.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bispecific antibody therapy-associated opportunistic infections: cytomegalovirus retinitis and chronic salmonellosis in a non-HIV patient. 双特异性抗体治疗相关的机会性感染：巨细胞病毒视网膜炎和慢性沙门氏菌病在一个非hiv患者。

IF 10.1 1区医学

Haematologica Pub Date : 2025-07-17 DOI: 10.3324/haematol.2025.287351

Maria R Cochran-Perez,Pritika Sharma,Jean-Sebastien Delisle,Max Schlesinger,Hussain Rao,Juan Trias,Marina Keller

引用次数: 0

Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation. 改变供体可以改善第一次同种异体干细胞移植失败患者的第二次移植结果。

IF 10.1 1区医学

Haematologica Pub Date : 2025-07-17 DOI: 10.3324/haematol.2025.287554

Rui Ma,Xiao-Yu Zhu,Yue Lu,Jia Chen,Li Xuan,Hai-Long Yuan,Yang Cao,Wei-Jie Cao,Xiao-Sheng Fang,Kou-Rong Miao,Xiao-Xia Hu,Hai Yi,Yan-Min Zhao,Yuan-Bin Wu,Ting Yang,Hong-Tao Wang,Yue Yin,Zhong-Ming Zhang,Xiao-Hui Zhang,Lan-Ping Xu,Yu Wang,Kai-Yan Liu,Xiao-Jun Huang,Yu-Qian Sun

{"title":"Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation.","authors":"Rui Ma,Xiao-Yu Zhu,Yue Lu,Jia Chen,Li Xuan,Hai-Long Yuan,Yang Cao,Wei-Jie Cao,Xiao-Sheng Fang,Kou-Rong Miao,Xiao-Xia Hu,Hai Yi,Yan-Min Zhao,Yuan-Bin Wu,Ting Yang,Hong-Tao Wang,Yue Yin,Zhong-Ming Zhang,Xiao-Hui Zhang,Lan-Ping Xu,Yu Wang,Kai-Yan Liu,Xiao-Jun Huang,Yu-Qian Sun","doi":"10.3324/haematol.2025.287554","DOIUrl":"https://doi.org/10.3324/haematol.2025.287554","url":null,"abstract":"A second transplantation is almost the only salvage for patients encountering graft failure (GF) following the first allogeneic stem cell transplantation. However, there were no standard protocols for second transplantations, and the role of changing donors remained controversial. We retrospectively studied 272 consecutive patients from 18 Chinese centers undergoing second transplantations due to GF, aiming to assess the impact of changing donors and factors affecting second transplantation outcomes. The primary endpoint was neutrophil engraftment. Other endpoints included platelet engraftment, graft versus host disease (GVHD), transplant related mortality (TRM), relapse, and survival. Of the 272 patients, 193 (71.0%) patients experienced primary GF, and 70.6% (192) used a different second donor. Neutrophil engraftment was achieved in 218 (86.3%) patients by d28, and platelet engraftment was achieved in 164 (70.0%) patients by d100. The 3-year cumulative incidence of acute GVHD, chronic GVHD, relapse, and TRM were 43.5%, 27.8%, 15.6%, and 44.6%, respectively. The 1-year and 3-year overall survival (OS) were 56.1% and 49.5%, respectively. Compared to using the same donor, changing donors significantly improved neutrophil (92.4% vs 71.4%, p.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"12 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment. 未接受治疗的新诊断急性髓性白血病患者的特点。

IF 10.1 1区医学

Haematologica Pub Date : 2025-07-17 DOI: 10.3324/haematol.2025.288105

Oudai Alkabbani,Yazan Jabban,Rong He,David Viswanatha,Kurt Bessonen,Patricia Greipp,Dragan Jevremovic,James M Foran,Talha Badar,Cecilia Arana Yi,Yael Kusne,Antoine N Saliba,Mehrdad Hefazi,Aasiya Matin,William J Hogan,Abhishek Mangaonkar,Hassan Alkhateeb,Mrinal Patnaik,Mithun Shah,Kebede Begna,Mark R Litzow,Aref Al-Kali

引用次数: 0

Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia. 节律性低剂量地西他滨和维妥乐治疗慢性髓单细胞白血病是安全的，并能减少单核细胞负担。

IF 10.1 1区医学

Haematologica Pub Date : 2025-07-17 DOI: 10.3324/haematol.2024.287253

Bradley Rockwell,Mendel Goldfinger,Ioannis Mantzaris,Aditi Shastri,Yogen Saunthararajah,Kira Gritsman,Alejandro R Sica,Noah Kornblum,Nishi Shah,David Levitz,Lauren C Shapiro,Ridhi Gupta,Anne Munoz,Aradhika Dhawan,Karen Fehn,Monica Comas,Jhannine Verceles,Dennis L Cooper,Marina Konopleva,Eric J Feldman,Amit Verma

引用次数: 0

PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia. 在t细胞急性淋巴细胞白血病中，PHF6与LMO2复合物相互作用。

IF 10.1 1区医学

Haematologica Pub Date : 2025-07-10 DOI: 10.3324/haematol.2024.287124

Vesna S Stanulović,Sarah Binhassan,Budoor A Jaber,Shimaa Alazmi,Fatma M B Saleman,Sandeep Potluri,Guy Pratt,Christian Ludwig,Douglas G Ward,Maarten Hoogenkamp

引用次数: 0

Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis. 非霍奇金淋巴瘤CD19 CAR - T治疗前桥接放疗的安全性和有效性：一项系统回顾和荟萃分析

IF 10.1 1区医学

Haematologica Pub Date : 2025-07-10 DOI: 10.3324/haematol.2025.287547

Mohammad Alhomoud,Rahma Ibrahim,Michelle Demetres,Kai Rejeski,Michael Scordo,Roni Shouval,Tobias Tix,Jeremie Martinet,Michelle Foley,Alexandra Gomez-Arteaga,Tsiporah Shore,Paul Pagnini,Mahmoud Aljurf,Monica L Guzman,Silvia Formenti,Joachim Yahalom,Koen Van Besien,Brandon S Imber,Zhengming Chen,Samuel Yamshon

{"title":"Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.","authors":"Mohammad Alhomoud,Rahma Ibrahim,Michelle Demetres,Kai Rejeski,Michael Scordo,Roni Shouval,Tobias Tix,Jeremie Martinet,Michelle Foley,Alexandra Gomez-Arteaga,Tsiporah Shore,Paul Pagnini,Mahmoud Aljurf,Monica L Guzman,Silvia Formenti,Joachim Yahalom,Koen Van Besien,Brandon S Imber,Zhengming Chen,Samuel Yamshon","doi":"10.3324/haematol.2025.287547","DOIUrl":"https://doi.org/10.3324/haematol.2025.287547","url":null,"abstract":"Bridging radiation therapy (BRT) is increasingly utilized prior to CART19 in NHL patients. However, its impact on CART19 outcomes is not established. We conducted a systematic review and meta-analysis to estimate the safety and efficacy of BRT prior to CART19 therapy. A comprehensive search was performed in databases from inception to October 2024. We identified 18 studies encompassed 538 adult NHL patients who received BRT prior to commercial CART19. Random-effect models were applied to explore meta-analysis outcomes. DLBCL was the most common diagnosis (73%), and axicabtagene ciloleucel was the most utilized product (67%). Bulky disease was present in 37%. Median BRT dose was 30 Gy delivered comprehensively to all sites of PET avid disease in 76% of cases. ORR to CART19 was 78.9%. At 1 year, PFS was 54.6% while OS was 71.2%. All-grade CRS was 80% while all-grade ICANS was 39.4%. Grade 3/4 CRS was 3.6% and grade 3/4 ICANS was 10.6%. Sensitivity analyses including studies with bulky disease and excluding studies with patients who also received systemic bridging therapy, demonstrated consistent results compared to the main study findings. Sub-group meta-regression showed similar results in studies that utilized BRT only compared to studies that utilized combined-modality treatment. In conclusion, this metaanalysis found that BRT use prior to CART19, whether as a standalone approach or in combination with systemic therapy, does not increase toxicity or compromise the efficacy of CART19 therapy in NHL. Furthermore, use of BRT is associated with low rate of CRS, even in patients with bulky disease.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"21 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144594091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0